1. FEIBA Prescribing Information.
  2. What is an inhibitor? National Hemophilia Foundation website. http://www.hemophilia.org/Bleeding-Disorders/Inhibitors-Other-Complications/Inhibitors-for-Consumers/What-is-an-Inhibitor. Accessed November 6, 2018.
  3. An introduction to hemophilia. In: All About Hemophilia: A Guide for Families. Montreal, Quebec, Canada: Canadian Hemophilia Society; 2010. http://www.hemophilia.ca/files/Chapter%2001.pdf. Accessed November 6, 2018.
  4. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8(3):280-287.
  5. The challenges of inhibitors. National Hemophilia Foundation website. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=239&contentid=418&rptname=inhibitors. Accessed November 6, 2018.
  6. Who is at risk for developing inhibitors? National Hemophilia Foundation website. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=232&contentid=411&rptname=inhibitors. Accessed November 6, 2018.
  7. Aledort LM, DiMichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia. 1998;4(1):68.
  8. Kempton CL. Inhibitors in previously treated patients: a review of the literature. Haemophilia. 2010;16(102):61-65.
  9. Kasper CK. Diagnosis and Management of Inhibitors for Factors VIII and IX: An Introductory Discussion for Physicians. Montreal, Quebec, Canada: World Federation of Hemophilia; 2004.
  10. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol. 2004;77(2):187-193.
  11. Peerlinck K, Jacquemin M. Characteristics of inhibitors in mild/moderate haemophilia A. Haemophilia. 2006;12(suppl 6):43-47.
  12. Soucie JM, Symons J IV, Evatt B, et al. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia. 2001;7(2):198-206.
  13. Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag. 2007;3(4):527-531.
  14. Rota M, Cortesi PA, Crea R, et al. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv. 2017;1(26):2637-2642.
  15. Data on file.
  16. Gomperts ED. FEIBA safety and tolerability profile. Haemophilia. 2006;12(suppl 5):14-19.
  17. Data on file.
  18. MASAC recommendation regarding the use of bypassing agents in patients with hemophilia A or B and inhibitors. MASAC Recommendation #167. National Hemophilia Foundation website. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=579. Accessed November 6, 2018.
  19. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004;10(suppl 2):3-9.
  20. Management of bleeds. In: All About Hemophilia: A Guide for Families. Montreal, Quebec, Canada: Canadian Hemophilia Society; 2010. http://www.hemophilia.ca/files/Chapter%2004.pdf. Accessed November 6, 2018.
  21. MASAC recommendation regarding prophylaxis with bypassing agents in patients with hemophilia and high titer inhibitors. MASAC Recommendation #220. National Hemophilia Foundation website. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Regarding-Prophylaxis-with-Bypassing-Agents-in-Patients-with-Hemophilia-and-High-Titer-Inhibitors. Accessed November 6, 2018.
  22. Medical and Scientific Advisory Council (MASAC). National Hemophilia Foundation website. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=156&contentid=335. Accessed November 6, 2018.
  23. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20(1):65-72.
  24. Do the 5! National Hemophilia Foundation Steps for Living website. http://stepsforliving.hemophilia.org/next-step/maintaining-a-healthy-body/do-the-5. Accessed November 6, 2018.
  25. Blood clots. Medical Dictionary website. http://medical-dictionary.thefreedictionary.com/Blood+Clots. Accessed November 6, 2018.
  26. Glossary. National Hemophilia Foundation website. https://www.hemophilia.org/Glossary. Accessed November 6, 2018.
Sign up
See LessMore

What is FEIBA?

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes

Detailed Important Risk Information

What is FEIBA?

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Use around the time of surgery
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Detailed Important Risk Information

  • Blood clots that block blood vessels and their effects have been reported during post-marketing surveillance following infusion of FEIBA, particularly following administration of high doses (above 200 units per kg per day) and/or in patients at risk for forming blood clots.
  • If you experience any of these side effects, call your doctor right away.